# INCB161734-101 (NCT06179160)

> A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

No report yet. It can be ordered.

- Drugs tested: INCB161734; INCB161734 plus cetuximab; INCB161734 plus retifanlimab
- Indication: KRAS G12D-mutated advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06179160
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Solid Tumors
- Interventions: INCB161734; Cetuximab; Retifanlimab; GEMNabP; mFOLFIRINOX; FOLFOX; FOLFIRI; INCA33890
- Enrollment: 710
- Primary outcome: Number of participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Number of participants with Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: Number of participants with TEAEs leading to dose modification or discontinuation

## Indexed commentary on INCB161734-101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=incb161734-101-nct06179160